Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity.

Autor: Santollani L; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Maiorino L; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Zhang YJ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Palmeri JR; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Stinson JA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Duhamel LR; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Qureshi K; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Suggs JR; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Porth OT; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Pinney W 3rd; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Msari RA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Walsh AA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Wittrup KD; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. wittrup@mit.edu.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. wittrup@mit.edu.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. wittrup@mit.edu., Irvine DJ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. djirvine@mit.edu.; Howard Hughes Medical Institute, Chevy Chase, MD, USA. djirvine@mit.edu.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. djirvine@mit.edu.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA. djirvine@mit.edu.; Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. djirvine@mit.edu.

Publikováno v: Nature immunology [Nat Immunol] 2024 Oct; Vol. 25 (10), pp. 1820-1829. Date of Electronic Publication: 2024 Aug 07.

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.

Autor: Saddawi-Konefka R; Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, CA, USA. rsaddawi@health.ucsd.edu.; Moores Cancer Center, UC San Diego, La Jolla, CA, USA. rsaddawi@health.ucsd.edu.; Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, CA, USA. rsaddawi@health.ucsd.edu., O'Farrell A; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA., Faraji F; Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, CA, USA.; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, CA, USA., Clubb L; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Allevato MM; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Jensen SM; Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR, USA., Yung BS; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Wang Z; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Wu VH; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Anang NA; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Msari RA; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Schokrpur S; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, CA, USA.; Department of Medicine, Division of Hematology-Oncology, UC San Diego School of Medicine, San Diego, CA, USA., Pietryga IF; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Molinolo AA; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Mesirov JP; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Department of Medicine, UC San Diego School of Medicine, La Jolla, CA, USA., Simon AB; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Department of Radiation Oncology, UC Irvine School of Medicine, Irvine, CA, USA., Fox BA; Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR, USA.; Department of Molecular Microbiology and Immunology, Oregon Health Science University, Portland, OR, USA., Bui JD; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Department of Pathology, UC San Diego School of Medicine, La Jolla, CA, USA., Sharabi A; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, CA, USA.; Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, San Diego, CA, USA., Cohen EEW; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, CA, USA.; Department of Medicine, Division of Hematology-Oncology, UC San Diego School of Medicine, San Diego, CA, USA., Califano JA; Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, CA, USA.; Moores Cancer Center, UC San Diego, La Jolla, CA, USA.; Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, CA, USA., Gutkind JS; Moores Cancer Center, UC San Diego, La Jolla, CA, USA. sgutkind@health.ucsd.edu.; Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, CA, USA. sgutkind@health.ucsd.edu.; Department of Pharmacology, UC San Diego, La Jolla, CA, USA. sgutkind@health.ucsd.edu.

Publikováno v: Nature communications [Nat Commun] 2022 Jul 25; Vol. 13 (1), pp. 4298. Date of Electronic Publication: 2022 Jul 25.